Modeling the Population Equity of Alzheimer Disease Treatments in the US.

ABSTRACT:

Importance

The arrival of new medications for Alzheimer disease (AD) has prompted efforts to measure their value using conventional cost-effectiveness analyses; however, these analyses focus on how much health improvement new medications generate per dollar spent. As AD disproportionately affects older adults, women, racial and ethnic minority individuals, and individuals with lower socioeconomic and educational levels, it is critical to also examine the health equity outcomes of treatment.

Objective

To estimate the health equity impact of a hypothetical disease-modifying treatment for early AD in the US and to examine targeted policies to mitigate health care disparities.

Design, setting, and participants

This economic evaluation, which used a distributional cost-eff

SUBMITTER: Synnott PG 

PROVIDER: S-EPMC11528311 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature